Tartaric Acid
Medchemexpress LLC 11-Methoxyyangonin | 2743-14-8 | 1 MG
11-Methoxyyangonin is a natural kavalactone.
- Purity: 99.44%
- Appearance: solid
- Color: light yellow to yellow
- For research use only
Selleck Chemical LLC ENMD-2076 L-()-Tartaric acid S2018-50mg
ENMD-2076 L-( )-Tartaric acid is the tartaric acid of ENMD-2076 selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1 86 nM 25-fold more selective for Aurora A than Aurora B and less potent to VEGFR2/KDR and VEGFR3 FGFR1 and FGFR2 and PDGFR Phase 2
Selleck Chemical LLC ENMD-2076 L-()-Tartaric acid S2018-5mg
ENMD-2076 L-( )-Tartaric acid is the tartaric acid of ENMD-2076 selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1 86 nM 25-fold more selective for Aurora A than Aurora B and less potent to VEGFR2/KDR and VEGFR3 FGFR1 and FGFR2 and PDGFR Phase 2
Selleck Chemical LLC ENMD-2076 S1181-5mg
ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1 86 nM 25-fold selective for Aurora A than over Aurora B and less potent to RET SRC NTRK1/TRKA CSF1R/FMS VEGFR2/KDR FGFR and PDGFR ENMD-2076 inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines with IC50 from 0 025 to 0 7 M which induces apoptosis and G2/M phase arrest Phase 2
Selleck Chemical LLC ENMD-2076 S1181-1g
ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1 86 nM 25-fold selective for Aurora A than over Aurora B and less potent to RET SRC NTRK1/TRKA CSF1R/FMS VEGFR2/KDR FGFR and PDGFR ENMD-2076 inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines with IC50 from 0 025 to 0 7 M which induces apoptosis and G2/M phase arrest Phase 2
Selleck Chemical LLC ENMD-2076 S1181-10mM/1mL
ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1 86 nM 25-fold selective for Aurora A than over Aurora B and less potent to RET SRC NTRK1/TRKA CSF1R/FMS VEGFR2/KDR FGFR and PDGFR ENMD-2076 inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines with IC50 from 0 025 to 0 7 M which induces apoptosis and G2/M phase arrest Phase 2
Apexbio Technology LLC ENMD-2076 934353-76-1 10mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Apexbio Technology LLC ENMD-2076 934353-76-1 50mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Apexbio Technology LLC ENMD-2076 934353-76-1 200mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Apexbio Technology LLC ENMD-2076 934353-76-1 5mg
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies
Apexbio Technology LLC ENMD-2076 934353-76-1 10mM (in 1mL DMSO)
ENMD-2076 (CAS 934353-76-1) is a selective inhibitor of Aurora A kinase (IC50 14 nM) and FLT3 (IC50 1 86 nM) with additional inhibitory activity against multiple tyrosine kinases implicated in angiogenesis and cell proliferation including RET FLT4/VEGFR3 SRC CSF1R NTRK1 FGFR1/2 VEGFR2/KDR LCK and PDGFR (IC50 1 86 120 nM) ENMD-2076 disrupts cell cycle progression by arresting cells in the G2/M phase through inhibition of Aurora kinases suppresses the PI3K/AKT signaling pathway and demonstrates cytotoxic effects in hematologic malignancy and solid tumor cell lines (in vitro IC50 25 700 nM) In vivo it reduces tumor growth and angiogenesis in xenograft models supporting its use in cancer research and antiangiogenic studies